(Sharecast News) - Avacta said on Monday that updated clinical data for its AVA6000 cancer therapy showed encouraging early efficacy signals in patients with salivary gland cancers, alongside a continuing favourable safety profile.
The AIM-traded clinical-stage biopharmaceutical company said updated Phase 1a/1b pharmacokinetic, safety, toxicity and preliminary efficacy data for faridoxorubicin,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE